Spravato (Esketamine) For Depression
A practical, evidence-aware guide to esketamine for treatment-resistant depression: who may be considered, what a supervised visit involves, and what benefits and risks to discuss.

In this article
When several depression treatments have not helped enough, it can feel as though the options are running out. Esketamine is one additional treatment clinicians may consider for some adults. It can act quickly for some people, but it is not a fit for everyone and requires careful, supervised care. Here is what the treatment is, what research suggests, and what questions can help you decide whether to explore it.
What esketamine is
Esketamine is the S-enantiomer of ketamine and works differently from many traditional antidepressants. It affects the glutamate system, including NMDA receptors. This distinct mechanism is one reason researchers have studied it for depression that has not improved enough with other treatments. The mechanism is not a promise of benefit for any one person.¹
The FDA-approved nasal spray, Spravato, is indicated for adults with treatment-resistant depression (TRD), either on its own or with an oral antidepressant. It is also indicated with an oral antidepressant for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. These are separate treatment situations that a qualified clinician evaluates individually.¹
What “treatment-resistant” means—and who may discuss it
TRD generally describes depression that has not improved adequately after trying appropriate treatments. The details matter: whether a treatment was taken long enough and at a therapeutic dose, side effects, other health conditions, and the person’s goals all shape what to consider next.
Esketamine is one option among several—not a last resort and not a shortcut around a full care plan. A prescriber can review prior treatments and discuss alternatives such as psychotherapy, other medication strategies, or other specialist treatments. The VA/DoD guideline treats esketamine as an option in advanced care rather than a usual initial medication choice.²
What the evidence can—and cannot—tell us
Clinical trials and reviews suggest that intranasal esketamine can reduce depressive symptoms for some people, and some participants notice change early in treatment. A 2025 review using individual participant data found a statistically significant average benefit when esketamine was added to an antidepressant, but the size of that average difference was modest and its meaning for an individual remains uncertain.³
For people who improve and continue into a maintenance phase, randomized-withdrawal studies support ongoing treatment as one way to lower relapse risk. That does not mean everyone responds, that benefits are permanent, or that treatment can be stopped without a plan. Follow-up and a shared decision with the care team remain important.¹,³
For the acute-suicidal-symptom indication, the FDA label specifically says effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Esketamine does not replace hospitalization or other urgent safety care when those are clinically needed. If you or someone else may be in immediate danger, contact emergency services or a crisis line now.¹
What a treatment visit is like
Esketamine nasal spray is administered in a certified health-care setting under the Spravato REMS safety program. The patient uses the device under staff supervision and is monitored for at least two hours afterward, including for sedation, dissociation, and changes in blood pressure. It is not a take-home nasal spray.¹
People generally need someone else to take them home and must not drive or operate machinery until the next day after a restful sleep. The care team explains the schedule, checks how treatment is going, and decides with the patient whether continuing makes sense.¹
Side effects and safety considerations
Common effects include feeling detached or dissociated, dizziness, nausea, sleepiness, a sense of spinning, headache, and temporary increases in blood pressure. These effects are often monitored during and after a session, but can be unsettling, so patients should tell the treatment team what they are experiencing.¹
The prescribing information also warns about sedation, respiratory depression, impaired attention and judgment, and abuse or misuse. Esketamine is a Schedule III controlled substance. A clinician will review medical history and other medicines—especially sedatives or substances that can affect alertness or breathing—and determine whether the potential benefits outweigh the risks.¹
Esketamine is not appropriate for everyone. Some blood-vessel conditions and a history of bleeding in the brain are among the label’s contraindications. Pregnancy, blood-pressure concerns, substance-use history, and other health factors should be discussed before treatment. Do not start, stop, or change medication based on an article.¹
Questions to take to your prescriber
You might ask: What makes esketamine relevant to my situation? What benefits are realistic to look for, and how will we measure them? What other options should I weigh? What will happen during monitoring, and what should I plan for after each visit? How will we handle side effects, cost or access, and the longer-term plan if I improve?
It is reasonable to feel both hopeful and cautious. Esketamine has given some people another path to discuss when depression has been hard to treat, while its supervised setting and safety profile deserve an honest conversation. You and your care team can make that decision together, with your history and priorities at the center.
References
- [1] DailyMed. SPRAVATO (esketamine) nasal spray: current U.S. prescribing information.
- [2] VA/DoD. Clinical Practice Guideline for the Management of Major Depressive Disorder (2022).
- [3] Esketamine for Major Depressive Disorder in Adults: A Registered Systematic Review and Individual Patient Data Meta-Analysis (2025).
- [4] FDA. SPRAVATO Risk Evaluation and Mitigation Strategy (REMS).
